Reported Saturday, Bristol Myers Squibb Presented New Interim Long-Term Efficacy Data From The EMERGENT-4 Trial Evaluating Karxt In Schizophrenia At The 2024 Annual Congress Of The SIRS
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb presented new interim long-term efficacy data from the EMERGENT-4 trial for KarXT in schizophrenia at the 2024 SIRS Congress, showing continued improvements in symptoms at 52 weeks, with over 75% of participants achieving more than 30% improvement.
April 08, 2024 | 7:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's KarXT demonstrates significant long-term efficacy in treating schizophrenia, with over 75% of participants showing substantial improvement.
The positive interim results from the EMERGENT-4 trial for KarXT, showing significant long-term improvements in schizophrenia symptoms, are likely to be viewed positively by investors and could lead to increased investor confidence in Bristol Myers Squibb's pipeline. This could result in a short-term positive impact on BMY's stock price.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90